Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis

Semaglutide for the treatment of nonalcoholic steatohepatitis

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, LEAN trial team, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679–690

    CAS  Article  Google Scholar 

  2. 2.

    Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, Vergès B, Marre M (2020) Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1‑3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab 46(2):100–109

    CAS  Article  Google Scholar 

  3. 3.

    Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Sabine Kahl.

Ethics declarations

Interessenkonflikt

S. Kahl gibt an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kahl, S. Semaglutid zur Behandlung der nichtalkoholischen Steatohepatitis. Diabetologe (2021). https://doi.org/10.1007/s11428-021-00733-z

Download citation